Objectives: The PediaFlow (HeartWare International, Inc, Framingham, Mass) is a miniature, implantable, rotodynamic, fully magnetically levitated, continuousflow pediatric ventricular assist device. The fourth-generation PediaFlow was evaluated in vitro and in vivo to characterize performance and biocompatibility.
HEART FAILURE IN ADULTS
Heart disease is the leading cause of mortality in adults internationally and domestically, responsible for 1 in every 7 deaths within the United States. 1 With circulatory assist device development spanning more than 5 decades for adults, multiple paradigm shifts from pulsatile total artificial hearts, to pulsatile (first generation) ventricular assist devices (VADs), to continuous-flow (CF) rotary blood pumps (RBPs) have revolutionized the field of mechanical circulatory support (MCS) in adults. By using centrifugal-or axial-flow designs with a single moving impeller, RBPs eliminate the flexible blood membranes, check valves, long cannulas, and tortuous blood paths required in prior pulsatile pumps. This increased simplicity allows for smaller blood-contacting surface area and reduced dead space, thereby reducing thrombosis potential and infection risks, in addition to decreasing the overall device size. 2 Likewise, controller size has been markedly reduced by the elimination of large percutaneous drivelines, compressors, vacuum pumps, solenoids, and large power supplies associated with positive-displacement VADs. 3 Supported by blood bearings/seals (second generation) or suspended by hydrodynamic or electromagnetic forces (third generation), RBPs are now the standard for chronic MCS support clinically. 3, 4 With multiple adult CF VADs approved by the Food and Drug Administration (FDA) for bridge-totransplant or destination therapy applications, these technologies have rescued thousands of adults with refractory end-stage heart failure with additional devices under development or in clinical trials. 5 
PEDIATRIC HEART FAILURE
Within the United States, 25% of all neonates born with a congenital heart defect will require invasive treatment within the first 12 months of life. 6 Approximately 1800 infants die of congenital heart disease each year, and an additional 350 develop cardiomyopathy. 7, 8 Children weighing less than 15 kg listed for cardiac transplantation have the highest waiting list mortality rate (17%) in all solid-organ transplantation categories. 9 Cardiac transplantation remains the standard of care for refractory heart failure, but with limited donor availability, only 56% of infants listed received an organ over the last decade. 10 Although MCS has successfully decreased waiting list mortality and has been used as a bridge-torecovery, availability of MCS devices for children remains limited.
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MECHANICAL CIRCULATORY SUPPORT FOR PEDIATRICS
Extracorporeal membrane oxygenation is used extensively for providing temporary cardiac support to children from neonates to adolescents. Although resource intensive, it is cost-effective, institutionally available, and rapidly initiated. 13 However, extracorporeal membrane oxygenation is indicated only for short durations requiring immobilization and sedation, and has a high complication rate related to bleeding and thromboembolism proportional to support length. 14 For adolescents with sufficient body surface area, the use of adult-indicated durable CF-VADs is supported by the PediMACs registry with a 6-month survival approaching 90% (n ¼ 126) since inception in 2012. 15 The majority of CF-VADs were implanted in patients 6 years of age or older because of device size, although there is a growing off-label use of the smaller HeartWare HVAD (Framingham, Mass) typically implanted with an outflow graft constriction or operated at lower speeds (revolutions per minute [RPM]) to maintain pediatric-appropriate flow rates [15] [16] [17] in younger patients. Unlike adults, however, currently the only FDAapproved pediatric-specific bridge-to-transplant MCS device is the Berlin Heart EXCOR (Berlin, Germany), a paracorporeal, pneumatically driven, pulsatile VAD that provides extended support for the pediatric population through the use of varying volume-sized pumps coupled to a large pneumatic driver. The potential of the EXCOR as a lifesaving technology for children with heart failure is reflected in our center's experience since 2004. 18 However, the EXCOR has a substantial risk profile with approximately 80% of patients experiencing at least 1 significant adverse event, the majority ($50%) from severe bleeding or infection, and is associated with frequent pump exchanges due to device thrombosis around the valve leaflets. 
MATERIALS AND METHODS Government Initiatives
Although there continues to be a need for next-generation pediatric MCS technology, the small market potential has limited commercial interest. Driven by the lack of progress for this underserved population, the National Heart, Lung, and Blood Institute's (NHLBI) Pediatric Circulatory Support Program awarded more than $22 million in 2004 to 5 separate consortia toward the development of novel pediatric MCS devices. 11 In 2010, NHLBI launched the Pumps for Kids, Infants, and Neonates (PumpKIN) -Pre-Clinical Program and awarded contracts ($24 million) to support 4 preclinical efforts (3 for pediatric devices funded under Pediatric Circulatory Support Program) to gain Investigational Device Exemption from the FDA. 20 The PediaFlow Consortium, consisting of the University of Pittsburgh, Children's Hospital of Pittsburgh, Carnegie Mellon University, and LaunchPoint Technologies (Goleta, Calif), received an award in both NHLBI Programs.
PediaFlow Development
As a participant in both NHLBI programs, we designed an implantable, mixed-flow, fully magnetically levitated (maglev), rotodynamic VAD to support the smallest (body surface area <0.5 m 2 with a cardiac index >3.0 L/min/m 2 ), and consequently most vulnerable, patients, for durations consistent with bridge-to-transplant wait list times, with the objective of minimizing MCS-associated serious adverse events. 9, 21 From the first prototype (PF1) demonstrating the feasibility and biocompatibility of a de novo, miniature maglev pump, the developmental evolution and miniaturization of the PediaFlow pediatric VAD (HeartWare International) summarized in Figure 1 involved implementation of turbomachinery principles outside of the usual operational ranges. 22, 23 Designed to operate at supercritical speeds (RPMs above resonance frequencies), the thirdgeneration PediaFlow (PF3) demonstrated excellent biocompatibility in vivo but maglev suspension instabilities limited flow rates to less than 1.0 L/min, necessitating further optimization and development. 23 Intended to provide up to 6 months of circulatory support for patients between 3 and 15 kg at flow rates of 0.3 to 1.5 L/min, the fourthgeneration PediaFlow (PF4) pediatric VAD is the result of more than 10 years of biomedical, mechanical, electrical, and computational engineering. Representing the latest pump topology designed to achieve the target flow rates, the PF4's optimized blood-flow path consists of a tapered cylindrical impeller with 4 blades on the conical inlet face, leading to a single 1.5-mm annular fluid gap region, before passing through a 3-vane flow straightener machined into the aft-housing upon exit. 24 Integrated ''quickconnect'' coupling mechanisms, recessed within the housing, enable direct attachment to the pump inlet and outlet (Figure 1, inset) . Approximately the size of AA battery, a decrease in size of approximately 75% from the initial PF1 prototype (Figure 2, A) , anatomic fit simulations suggest that the PF4 can be fully implanted in infants as small as 5 kg through placement behind the left rectus abdominus muscle with a single percutaneous driveline for electrical power. FIGURE 1. Evolution and miniaturization of the PediaFlow from the PF1 to the PF4 pediatric VAD and pump topology (inset). PF1, First-generation PediaFlow; PF2, second-generation PediaFlow; PF3, third-generation PediaFlow; PF4, fourth-generation PediaFlow.
In Vitro Assessment
Benchtop evaluation of the PF4 was performed to confirm hemodynamic performance and characterize hemolysis potential. Physiologic flow rate and pressure measurements were simulated in a closed flow loop using a 2.39 centipoise blood analog glycerol-solution to generate characteristic pump ''H-Q'' curves following previously published methods. 22 By using accepted standards, in vitro hemolysis testing was performed on several PF4 prototypes (Table E1 in Appendix E1) before in vivo implantation using purchased, citrated ovine whole blood (Lampire Inc, Ottsville, Pa) with a minimum total plasma protein concentration of 6.0 g/dL within 3 days of venipuncture. [25] [26] [27] [28] The clinically used, centrifugal PediMag (Thoratec, Pleasanton, Calif) pump served as a control for comparison. The Normalized Index of Hemolysis (NIH) was calculated for each pediatric hemodynamic test condition as follows 26 :
where DHb is the measured change in plasma free hemoglobin (g/L), V is the total circuit volume (L), Ht is the blood hematocrit (%), Q is the flow rate (L/min), and T is the test duration (min).
In Vivo Evaluation
Under University of Pittsburgh Institutional Animal Care and Use Committee-approved protocols at the McGowan Institute's Center for Preclinical Studies, 6 PF4 prototypes were implanted in lambs (n ¼ 11, 19.0-30.3 kg) without cardiopulmonary bypass to evaluate the chronic in vivo hemodynamic performance and biocompatibility of the PediaFlow and develop the implantable components (Table E2 in Appendix E1). Anesthesia, surgical approach, insertion, and postoperative management for the PF4 implants were similar to the 72-day PF3 implant described previously. 22, 23 Three sham studies, in which the aforementioned implant procedure was followed without actual device placement, were performed to serve as complementary surgical controls (Appendix E2). Blood samples were drawn at regular intervals during the course of the studies for hematology and biocompatibility assessments, including plasma-free hemoglobin, fibrinogen concentration, and platelet activation and functionality assays, followed by a complete necropsy and pump component examination. 22, 29 A summary of the initial PF4 implant findings and design iterations, describing the concurrent development of the inflow cannula and outflow graft, can be found in Appendix E3.
Fourth-Generation PediaFlow Implantable Design
Detailed here are the most recent PF4 implants (n ¼ 2) using the de novo designed 5-mm reinforced inflow cannula featuring a parabolic-shaped inlet entrance and detachable sewing ring to unload the left ventricle (LV) (Figure 2 , B) and a 6-mm Gelweave (Vascutek Ltd, Renfrewshire, Scotland, UK) outflow graft with graduated strain relief to return blood to the aorta (Figure 2 , C).
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Surgical procedure with these implantable components varied only by first attaching the detachable sewing ring to the LV apex using pledgeted sutures after gaining access. After full anticoagulation with heparin, the outflow graft was anastomosed to the descending thoracic aorta and back-flushed before mating the graft connector to the pump outlet. The parabolic inflow cannula was inserted through the sewing ring after a cruciate incision without myocardium removal and a wet connection made to the pump inlet by the simultaneous removal of the inflow obturator and partial unclamping of the outflow graft. A perivascular ultrasonic probe (Transonic Systems, Ithaca, NY) was placed on the outflow graft to measure pump flow rate. Pump support was initiated and cannula depth optimized before thoracotomy closure. Rotational speed was adjusted as needed for a target flow rate of 1.5 L/min.
RESULTS
Hemodynamic Performance In Vitro
The characteristic performance curves of the PF4 highlighted an expanded operating range between 0.3 and 2.0 L/min at physiologically relevant pressure ranges, a marked improvement to PF3 (Figure 3 , A). Hemolysis (NIH) varied somewhat among PF4 prototypes but was very low at the 3 pediatric flow rates tested and comparable to the PediMag control ( Figure 3 , B). 
Implantation and Operation
The last implants with the PF4 prototypes and implantable components were unremarkable for a study duration of 14 and 60 days. Pump support was initiated within 1 hour after first incision, achieving flow rates up to 2.0 L/min before reducing motor speed (RPM) to maintain a target flow rate of 1.5 L/min after chest closure (Figure 4 , A). Because of the difficulty of titrating anticoagulation for an activated clotting time target of 180 to 200 seconds during the previous PF3 study, a continuous infusion of heparin was maintained at 20 UI/kg/h beginning on postoperative days 2 and 7 for PF4-S10 (60-day implant) and PF4-S11 (14-day implant), respectively (Figure 4, D) .
In Vivo Biocompatibility
During the PediaFlow implants, hemodynamic performance was within the pediatric physiologic range, whereas serum chemistry, hematology, and cellular biocompatibility parameters closely followed the trends observed in the 3 surgical control sham studies (Table E3 in Appendix E1). Plasma-free hemoglobin remained within preoperative levels and fibrinogen concentration values for the implants, and surgical control animals returned to baseline by postoperative day 14 ( Figure 5 , B and C). Platelet activation, measured by flow cytometry as percent of CD62pþ platelets, had a marked postsurgical response before returning to preoperative baseline values by postoperative day 10. Throughout the studies, platelets remained responsive to stimulation with platelet activating factor (Figure 4 , E).
Necropsy
Examination of the heart, lungs, liver, and spleen for both the PF3 and latest PF4 implants was unremarkable. The inflow cannulae were well healed within the LV apex with no myocardial injury evident, and the blood contacting surfaces of the pump, cannulae, and outflow grafts free of . Results of the PF4 ovine studies using the current-design cannulae system (PF4-S10, PF4-S11), in comparison with the previous thirdgeneration chronic implant (PF3-S01) and the nonimplanted surgical control shams (n ¼ 3, mean AE standard deviation): A, Measured pump flow rate (Q) for the implanted animals (gaps indicate durations of signal loss during postoperative acoustic recoupling of the outflow graft probe). Hematologic and hemocompatibility measurements including plasma-free hemoglobin (B), fibrinogen (C), activated clotting time (D), and platelet biocompatibility (E) as determined by the time course of platelet activation by P-selectin expression and platelet functionality by agonist stimulation using platelet activating factor. ACT, Activated clotting time; FB, fibrinogen; PAF, platelet activating factor; PF3, third-generation PediaFlow; PF4, fourth-generation PediaFlow; plfHb, plasma-free hemoglobin; POD, postoperative day.
DISCUSSION
Implantable pediatric VADs have the potential to expand the number of children in heart failure rescued by MCS. 31 The use of RBPs for the treatment of pediatric heart failure is appealing by reducing the immobilization and inpatient restrictions that are currently associated with the EXCOR. Although the successful miniaturization of CF VADs will affect pediatric MCS options, the small market size and regulatory process create a significant entry barrier for this technology in the United States. Supported by the bench and preclinical findings reported in this article, the PediaFlow has the potential to serve as a bridge-to-transplant or bridge-to-recovery device.
Consistent with the program goals for the 2 NHLBI contracts under which this work was conducted, the primary considerations for the design and development of the PediaFlow were miniaturization and reduction of serious adverse events by maximizing cellular biocompatibility, as judged on the bench and in situ. 23, 32, 33 In silico optimization of the rotodynamics, magnetodynamics, heat transfer, and fluid dynamics yielded 4 successively smaller prototypes that were built and tested both in vitro and in vivo. Figure 1 displays the marked reduction in profile of the PediaFlow design in successive generations of prototypes (PF1-PF4), with the PF4 prototype approximating the size of an AA cell battery (Figure 2, A) . By increasing the voice (levitation) coil to motor stator size-ratio to enhance rotor stability and optimizing the pump blading from PF3, flow rates were improved enabling PF4 to reach the target design goals. With an NIH of less than 0.02 g/100 L for the final PF4 prototypes, the PediaFlow PF4 device is nonhemolytic (eg, the NIH for the PF4 approximates that of the maglev PediMag) and less than published literature values for both adult and pediatric devices. 26, 34, 35 We attribute the absence of hemolysis to the fully magnetically levitated rotor design, the optimized single blood flow path, and the relatively large annular gap (1.5 mm), which eliminates the need for bearings or seals, thereby reducing hemolytic potential. Because each PF4 pump was hand-built, the variation in NIH among prototypes is likely due to assembly and polishing tolerances.
Another design consideration for the PediaFlow technology is that pediatric MCS should be rapidly deployable and customizable to support the representative patient population. The use of cardiopulmonary bypass for VAD implantation is expected; however, limiting on-pump time remains ideal. Within this context, and for the PediaFlow inflow cannula, the removable sewing ring provides accurate and unencumbered placement onto the heart apex before allowing insertion and tool-less securement of the inflow body within the LV. The reinforced parabolic-shaped inflow tip (Figure 2 , B) eases insertion and serves as a clinical marker for echocardiography perioperatively to adjust insertion depth and postoperatively when assessing cannula position. Along with the preassembled outflow graft and quick connect mechanisms (Figure 2, C) , pump support was initiated in the latest studies in less than 1 hour from first incision without the use of cardiopulmonary bypass. Without any evidence of ventricular suction supported by explant analysis in the PF3 and PF4 implant studies, we hypothesize that the additional flow paths provided by the inlet shape geometry render the parabolic tip resistant to entrapment and less sensitive to positional variations. 30 Although in vivo analysis is performed in healthy animals and does not necessarily reflect the causes in children (ie, congenital, dilated, or restrictive cardiomyopathies), the results are nonetheless encouraging. The biocompatibility findings in vivo ( Figure 5 ) and explant analyses (Figures 6  and 7) are consistent with the in vitro results demonstrating no hemolysis, platelet activation, or platelet dysfunction during implant periods up to 2 months. The lack of documented renal insufficiency or other evidence of thrombogenesis or thromboembolic events with only relatively low-dose heparin and subtherapeutic activated clotting times is especially promising toward the design goal for the PediaFlow pediatric VAD of solely antiplatelet therapies to minimize bleeding risk clinically. 32, 33 Additional implants using the current PF4 design and components are necessary to demonstrate reproducibility of the preclinical assessment for Investigation Device Exemption application.
CONCLUSIONS
This report is the culmination of 10 years of NHLBIsupported development of a miniaturized, implantable RBP for the chronic support of infants/small children with congenital or acquired cardiac defects (Video 1). More than 20 design variations were evaluated and judged on the basis of a multicomponent objective function that factored several criteria, including anatomic fit, cellular biocompatibility, heat generation and transfer, magnetically levitated suspension robustness, and manufacturability. 23 The design was improved and miniaturized through successive pump prototypes using computational fluid dynamics to minimize flow-induced blood damage via modification of the geometry of the predicted blood flow path. 24 The pump housing was modified to improve surgical fixation and the inflow/outflow attachments optimized to permit ease of insertion according to human factors engineering principles.
The data presented document the exceptional biocompatibility and the potential of safely providing chronic MCS to neonates and infants using a miniature, implantable, magnetically levitated, rotodynamic blood pump. Per the requirements of the NHLBI contract programs, the PediaFlow has been designated by the FDA as a Humanitarian Use Device for ''mechanical circulatory support in neonates, infants, and toddlers weighing up to 20 kg as a bridge to transplant, a bridge to other therapeutic intervention such as surgery, or a bridge to recovery.'' This important designation provides insight as to the remaining preclinical testing (both on the bench and in vivo) to be undertaken. Although accurate flow estimation has been achieved ( Figure E1 in Appendix E1), work remains, including the final prototyping and testing of a clinical-use controller, which is required for the final preclinical studies in anticipation of submitting an Investigational Device Exemption application to the FDA.
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APPENDIX E2 Third-Generation PediaFlow Surgical Methods
The PF3 was implanted in a healthy lamb for 72 days in accordance with the Institutional Animal Care and Use Committee guidelines at the University of Pittsburgh. E1 The pump was introduced into the circulation as an LV assist device, interposed between the LV and descending thoracic aorta. Surgical access was gained through a left thoracotomy, followed by heparinization for a target activated clotting time greater than 300 seconds. A modified wire-reinforced polyurethane cannula (18F DLP, Medtronic, Minneapolis, Minn) was inserted into the apex of the LV through a stab incision and secured with a sewing ring fashioned from thick surgical felt (PTFE, C.R. Bard, Murray Hill, NJ). The outflow from the PF3 was 6-mm diameter polyester vascular graft (Vascutek Ltd, Renfrewshire, Scotland, UK) anastomosed to the descending thoracic aorta using a partial occlusion clamp. The pump was operated at a fixed speed of 14.5 kilo RPM. The flow rate was measured via an ultrasonic transit-time flow probe (Transonic Inc, Ithaca, NY) attached to the outflow graft. Throughout the study, pump flow, power consumption, and carotid blood pressure were recorded. Hemorheology and serum chemistry values were collected daily to assess the biological impact of the pump on blood damage and organ function.
Surgical Sham (Control) Studies
Three ''sham'' implants were performed for an intended 28-day duration for the purpose of obtaining ''control'' biocompatibility data for the PediaFlow implantations.
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These sham surgical implants mimic a full PediaFlow implant study with the exception of device insertion and allow us to account for surgery and postoperative recovery on rheology, platelet activation, and other biocompatibility indices of interest. Because preoperative jugular venipuncture samples are prone to artifact from needle sticking an awake animal, E2 a jugular venous catheter was placed under general anesthesia 1 week before sham surgery for collection of baseline biocompatibility parameters (ie, platelet activation, plasma free hemoglobin, and fibrinogen).
For the sham surgical procedure, after intubation and induction of anesthesia, the existing venous catheter in the left jugular vein was replaced and an arterial catheter was inserted in the left carotid artery. The thorax was entered via a left, fourth interspace thoracotomy, and the LV apex and descending aorta were exposed. The animal was anticoagulated with heparin to maintain the whole blood activated clotting time at 1.5 to 2.0 times baseline. A lubricated sewing ring was fixed on the LV apex and a stab incision was made in the LV apex, which was then sutured closed. A 3-cm length of 6-mm diameter Gelweave (Vascutek Ltd, Renfrewshire, Scotland, UK) graft was connected in an end-to-side fashion to the descending thoracic aorta to duplicate the pump outflow graft and anastomosis site. The graft was then ''tied off'' to prevent graft material being in contact with the blood.
Surgery proceeded without any major complications, the animals recovered from anesthesia and were returned to the intensive care unit, where they were monitored for the duration of the study. Recovery and follow-up were uneventful with hemodynamic and respiratory parameters remaining within normal limits. During follow-up periods, the animals were cared for exactly as the 72-day animal implanted with the PF3. After meeting the intended 28-day study period, the 3 sham experiments were electively ended for gross necropsy examination (Table E4) . 
APPENDIX E3
Fourth-Generation PediaFlow In Vivo Developmental Summary A total of 11 (n ¼ 11) in vivo ovine studies were performed with the PF4 pumps to develop, assess, and refine the implantable peripherals in addition to evaluating device hemodynamics and biocompatibility (Table E2 ). The initial 9 implants led to the parabolic-inflow cannula and outflow graft assembly design used together in the most recent implants (PF4-S10, PF4-S11) that are presented in the article.
Pump Connectors
Introduced with the PF4 prototypes was a compact, toolless, ''quick-connect'' coupling used with both the inflow cannula and the outflow graft assembly. Consisting of a nitinol-wire retaining clasp on the pump mating face and a flanged inlet/outlet adapter, attachment or removal of the cannula/graft is achieved by depressing the loop to concentrically deform the 2 guidewires that hold the radial flange in place ( Figure E2, A) . After initial wet-to-wet connections during surgical implantation were less than successful ( Figure E2, B) , a reduced flange diameter adapter was used for the PF4-S04 and subsequent implants that eliminated difficulties with nonseated pump connections ( Figure E2 , C).
Outflow Tract Assembly
As described in Table E5 , 3 outflow assembly iterations were implanted in conjunction with the PF4 in vivo studies. Although previous-generation PediaFlow studies used polyester-based outflow grafts (including the 72-day PF3-S01 implant), concerns about commercial availability and patency led to the selection of an ePTFE-based graft for the initial PF4 implants. Despite evaluating 2 different ePTFE styles, continuing issues with excessive fluid and plasma protein loss (ie, ''graft weep'') led to the decision to return to the Gelweave grafts previously used successfully.
Inflow Cannula
Continuing the transition from modified, off-the-shelf, commercial hardware to PediaFlow-specific implantable components, a bevel-type inflow cannula was developed, modeled after the EXCOR LV drainage cannula (Table  E6) . Limited by premature ventricular suction or myocardial occlusion of the inlet tip, perioperative efforts to gain adequate drainage led to kinking of the inflow cannula evident at study termination ( Figure E3 ).
After extensive redesign and ex vivo testing, E3 the new suction-resistant parabolic-type inflow cannula, depicted in Figure 2 , B, in the main article, was used in studies PF4-S10 and PF4-S11 with great success.
Hemocompatibility Findings
Despite the repeated challenges with the implantable peripherals in vivo, hemocompatibility as measured by plasma-free hemoglobin remained below 20 mg/dL for 7 of the 9 preliminary implants ( Figure E4 ). FIGURE E2 . The PF4 quick-connect attachment mechanism: The initial full-flange design was difficult to attach (A) and prone to misalignment in vivo (B). C, The revised design with a smaller flange size to ease insertion past the guidewires. 1651.e7 The Journal of Thoracic and Cardiovascular Surgery c October 2018
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